thrombopoietin receptor agonists
Treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a medical or dental procedure.
Increases platelet production by initiating proliferation and differentiation of megakaryocytes from bone marrow progenitor cells.
Absorption: 66–69% absorbed following oral administration.
Distribution: Widely distributed to tissues.
Protein Binding: >96%.
Metabolism and Excretion: Primarily metabolized by CYP2C9 and CYP3A4 isoenzymes; primarily eliminated in feces (34% as unchanged drug).
Half-life: 19 hr.
TIME/ACTION PROFILE (effect on platelet count)
|PO||3–5 days||10–13 days||2 wk|
Use Cautiously in:
CNS: fatigue, headache
CV: THROMBOEMBOLISM, peripheral edema
F and E: hyponatremia
GI: abdominal pain, nausea
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
PO (Adults) Platelet count <40 x 109/L–60 mg once daily for 5 days (should be initiated 10–13 days prior to scheduled procedure; procedure should be performed 5–8 days after last dose); Platelet count 40–<50 x 109/L–40 mg once daily for 5 days (should be initiated 10–13 days prior to scheduled procedure; procedure should be performed 5–8 days after last dose.
Tablets: 20 mg
Lab Test Considerations:
Obtain platelet count before starting therapy and on day of procedure to make sure platelet count is adequate.
Decreased requirement for platelet transfusions or rescue procedures for bleeding.
Emergency Central is a collection of disease, drug, and test information including 5-Minute Emergency Medicine Consult, Davis’s Drug, McGraw-Hill Medical’s Diagnosaurus®, Pocket Guide to Diagnostic Tests, and MEDLINE Journals created for emergency medicine professionals. Complete Product Information.